Tyra Biosciences, Inc. TYRA Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -36.9%+3.0pp | -39.8%-5.1pp | -34.7%-3.5pp | -31.2%-4.2pp | -27%+4.6pp | |
| Return on assets | -34.7%+2.4pp | -37.1%-4.4pp | -32.7%-3.1pp | -29.6%-3.9pp | -25.8%+3.6pp | |
| Return on invested capital | -53.2%+6.5pp | -59.7%-8.2pp | -51.5%-2.1pp | -49.4%+11.9pp | -61.3%-10.5pp | |
| Liquidity | ||||||
| Current ratio | 20.5×+5.8× | 14.7×-3.0× | 17.7×-4.2× | 21.9×-0.8× | 22.8×-1.0× | |
| Quick ratio | 20.5×+5.8× | 14.7×-3.0× | 17.7×-4.2× | 21.9×-0.8× | 22.8×-1.0× | |
| Cash ratio | 4.4×+0.1× | 4.3×+0.4× | 3.9×-3.3× | 7.2×+0.1× | 7.1×+0.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.28+44.3% | $4.35-7.5% | $4.70-7.3% | $5.07-6.9% | $5.45-9.1% | |
| Valuation | ||||||
| Market capitalization | $2.06B+47.0% | $1.4B+88.2% | $745.63M+44.0% | $517.95M+4.9% | $493.74M-29.8% | |
| Enterprise value | $1.98B+49.0% | $1.33B+93.1% | $689.59M+62.1% | $425.49M+6.6% | $399.14M-35.4% | |
| Price / book | 5.3×-0.1× | 5.4×+2.8× | 2.7×+0.9× | 1.7×+0.2× | 1.5×-0.5× | |
| Free cash flow yield | -5%+1.8pp | -6.8%+5.4pp | -12.2%+4.5pp | -16.7%-1.8pp | -14.9%-4.9pp | |
| Earnings yield | -6.4%+2.2pp | -8.5%+6.4pp | -15%+5.5pp | -20.4%-0.9pp | -19.5%-7.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Tyra Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Tyra Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.